Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn, Richard S; Dering, Judy; Ginther, Charles; Wilson, Cindy A; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J

Finn, Richard S; Dering, Judy; Ginther, Charles; Wilson, Cindy A; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.

Affiliation

Finn RS; Department of Medicine, Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, Los Angeles, CA 90095, USA. rfinn@mednet.ucla.edu

Breast Cancer Res Treat ; 105(3): 319-26, 2007 Nov.

Article in En | MEDLINE | ID: mdl-17268817

Subject(s)

Breast Neoplasms/enzymology; Breast Neoplasms/pathology; Protein Kinase Inhibitors/pharmacology; Proto-Oncogene Proteins c-abl/antagonists & inhibitors; Pyrimidines/pharmacology; Thiazoles/pharmacology; src-Family Kinases/antagonists & inhibitors; Administration, Oral; Breast Neoplasms/classification; Breast Neoplasms/genetics; Cell Line, Tumor; Cell Proliferation/drug effects; Dasatinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic/drug effects; Humans; Keratins/genetics; Proto-Oncogene Proteins c-abl/metabolism; Pyrimidines/administration & dosage; Sensitivity and Specificity; Thiazoles/administration & dosage; Vimentin/genetics; src-Family Kinases/metabolism

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Thiazoles / Breast Neoplasms / Proto-Oncogene Proteins c-abl / Src-Family Kinases / Protein Kinase Inhibitors Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Breast Cancer Res Treat Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links